169 related articles for article (PubMed ID: 28660989)
1. Cinacalcet as symptomatic treatment of hypercalcaemia in primary hyperparathyroidism prior to surgery.
Misiorowski W; Zgliczyński W
Endokrynol Pol; 2017; 68(3):306-310. PubMed ID: 28660989
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism.
Takeuchi Y; Takahashi S; Miura D; Katagiri M; Nakashima N; Ohishi H; Shimazaki R; Tominaga Y
J Bone Miner Metab; 2017 Nov; 35(6):616-622. PubMed ID: 27873072
[TBL] [Abstract][Full Text] [Related]
3. Short-term medical treatment of hypercalcaemia in primary hyperparathyroidism predicts symptomatic response after parathyroidectomy.
Koman A; Ohlsson S; Bränström R; Pernow Y; Bränström R; Nilsson IL
Br J Surg; 2019 Dec; 106(13):1810-1818. PubMed ID: 31595982
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet-Associated Resolution of Primary Hyperparathyroidism in a Patient With Normal Kidney Function.
Nguyen S; Gosmanova EO; Gosmanov AR
J Investig Med High Impact Case Rep; 2020; 8():2324709620936836. PubMed ID: 32583691
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.
Peacock M; Bilezikian JP; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
J Clin Endocrinol Metab; 2011 Jan; 96(1):E9-18. PubMed ID: 20943783
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.
Marcocci C; Chanson P; Shoback D; Bilezikian J; Fernandez-Cruz L; Orgiazzi J; Henzen C; Cheng S; Sterling LR; Lu J; Peacock M
J Clin Endocrinol Metab; 2009 Aug; 94(8):2766-72. PubMed ID: 19470620
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
Zavvos V; Fyssa L; Papasotiriou M; Papachristou E; Ntrinias T; Savvidaki E; Goumenos DS
Exp Clin Transplant; 2018 Jun; 16(3):287-293. PubMed ID: 29108515
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic challenges in elderly patients with symptomatic hypercalcaemia caused by primary hyperparathyroidism.
Jacobs L; Samson MM; Verhaar HJ; Koek HL
Neth J Med; 2012 Jan; 70(1):35-8. PubMed ID: 22271812
[TBL] [Abstract][Full Text] [Related]
9. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
10. Reduction in parathyroid adenomas by cinacalcet therapy in patients with primary hyperparathyroidism.
Minezaki M; Takashi Y; Ochi K; Mitsuoka R; Yamao Y; Kudo T; Kawanami D; Kobayashi K; Abe I
J Bone Miner Metab; 2021 Jul; 39(4):583-588. PubMed ID: 33409573
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Persistent Hypercalcemia and Hyperparathyroidism With Cinacalcet After Successful Kidney Transplantation.
Ważna-Jabłońska E; Gałązka Z; Durlik M
Transplant Proc; 2016 Jun; 48(5):1623-5. PubMed ID: 27496458
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
Warady BA; Iles JN; Ariceta G; Dehmel B; Hidalgo G; Jiang X; Laskin B; Shahinfar S; Vande Walle J; Schaefer F
Pediatr Nephrol; 2019 Mar; 34(3):475-486. PubMed ID: 30506144
[TBL] [Abstract][Full Text] [Related]
13. Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with cinacalcet.
Guerra R; Auyanet I; Fernández EJ; Pérez MÁ; Bosch E; Ramírez A; Suria S; Checa MD
J Nephrol; 2011; 24(1):78-82. PubMed ID: 20437396
[TBL] [Abstract][Full Text] [Related]
14. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.
Khan A; Bilezikian J; Bone H; Gurevich A; Lakatos P; Misiorowski W; Rozhinskaya L; Trotman ML; Tóth M
Eur J Endocrinol; 2015 May; 172(5):527-35. PubMed ID: 25637076
[TBL] [Abstract][Full Text] [Related]
16. [Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery].
Arranz Martín A; Azcárate Villalón A; Luque Ramírez M; Santana Durán B; Marazuela Azpíroz M; Paniagua Ruiz A; Carraro R; Gómez Pan A
Endocrinol Nutr; 2011 Jan; 58(1):24-31. PubMed ID: 21277266
[TBL] [Abstract][Full Text] [Related]
17. Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication.
Marotta V; Di Somma C; Rubino M; Sciammarella C; Del Prete M; Marciello F; Ramundo V; Circelli L; Buonomano P; Modica R; Vitale M; Colao A; Faggiano A
Endocrine; 2015 May; 49(1):274-8. PubMed ID: 25123977
[No Abstract] [Full Text] [Related]
18. Experience with cinacalcet in primary hyperparathyroidism: results after 1 year of treatment.
Luque-Fernández I; García-Martín A; Luque-Pazos A
Ther Adv Endocrinol Metab; 2013 Jun; 4(3):77-81. PubMed ID: 23730501
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal.
Paschoalin RP; Torregrosa JV; Barros X; Durán CE; Campistol JM
Transplant Proc; 2012 Oct; 44(8):2376-8. PubMed ID: 23026597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
